Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer
Authors:
Open Access
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 147, 91-98
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2018
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2018
- PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole SectionsJournal of Thoracic Oncology, 2018
- PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variabilityLaboratory Investigation, 2017
- Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana’s PlatformJournal of Thoracic Oncology, 2016
- Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1Archives of Pathology & Laboratory Medicine, 2016
- Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIsJournal of Thoracic Oncology, 2016
- Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsClinical Cancer Research, 2015
- Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung CancerClinical Lung Cancer, 2015